Combantrin-1

Quick links to important sections

Combantrin-1

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Combantrin-1

Property Description
Active Ingredient Mebendazole
Form Chewable tablet
Pharmacological Class Anthelmintic
General Therapeutic Role Anti-parasitic agent
Origin Synthetic compound (Benzimidazole derivative)

1. Classification and Chemical Origin of Combantrin-1

Combantrin-1 is an anti-parasitic medication defined by its single active ingredient, Mebendazole, which functions as a broad-spectrum anthelmintic agent. This drug is a synthetic compound that chemically belongs to the Benzimidazole derivative class, a group clinically recognized for its reliable efficacy against parasitic infestations. The classification as an anthelmintic confirms its primary therapeutic role is focused on the elimination of parasitic worms, or helminths, from the host organism.

2. Composition and Pharmaceutical Form

The medicine is manufactured as an oral solid dosage form, specifically a chewable tablet, designed for straightforward consumption, making it particularly suitable for family use. The product's composition is centered exclusively on Mebendazole, combined with pharmaceutical excipients that facilitate the tablet's structure and flavor properties. The final preparation is typically intended for single-dose treatment in appropriate cases, a differentiating feature that simplifies administration compared to multi-day courses. This approach capitalizes on Mebendazole's characteristic poor systemic absorption, ensuring the drug remains concentrated in the gastrointestinal tract, where the parasites are located.

3. General Therapeutic Role and High-Level Function

The general purpose of Combantrin-1 is to serve as an anti-parasitic drug against the condition of helminthiasis. A typical use scenario involves treating intestinal parasitic infections common in school-age children. Its mechanism achieves this goal by interfering with the worm’s ability to utilize vital sugars and hindering the formation of necessary internal cell structures, leading to the parasite's eventual immobilization and clearance. This high-level functional goal positions the medication as a core agent for eliminating these pathogenic organisms from the digestive system.

What side effects are possible with Combantrin-1?

Possible Side Effects and Safety Information

Combantrin-1 (Mebendazole) is generally well-tolerated, with side effects primarily concerning the gastrointestinal system. Adverse reactions are formally categorized by frequency and system-organ class in regulatory documentation.


Common and Uncommon Adverse Reactions

The most commonly reported adverse events include abdominal pain (Common), abdominal discomfort, diarrhea, flatulence, nausea, and vomiting (Uncommon or frequency not reported). Other documented effects include headache, dizziness, and rash.

Serious and Clinically Significant Risks

Although rare, regulatory records document reports of serious systemic adverse reactions that warrant attention:

  • Hematologic Effects: Neutropenia and agranulocytosis (low white blood cell counts) have been reported, particularly with higher doses or prolonged therapy. Monitoring of blood counts may be necessary.
  • Dermatologic Reactions: Severe skin conditions, including Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), are rare but life-threatening risks.
  • Hepatobiliary Disorders: Reports include hepatitis and abnormal liver function tests.
  • Nervous System: Convulsions/seizures have been reported post-marketing, especially in infants.

Safety Restrictions and Contraindications

  • Hypersensitivity: The drug is contraindicated in individuals with a known allergy to Mebendazole or its excipients.
  • Age Restriction: It is contraindicated in children under 1 year of age for mass treatment due to the risk of convulsion.
  • Drug Interaction: The concomitant use of Mebendazole and Metronidazole is specifically discouraged due to an increased risk of severe skin reactions (SJS/TEN).
  • Specific Populations: Caution is advised in patients with pre-existing hepatic impairment, as higher systemic drug levels may occur. The drug's use during pregnancy or lactation should only occur under the advice of a healthcare professional, as animal studies have indicated developmental risks.

This safety information establishes the profile of risks, highlighting that while mild gastrointestinal issues are common, patients must be aware of the rare potential for serious hematologic, hepatic, and skin-related adverse events, especially in the context of specific drug interactions or patient populations.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documentation defines the overdose profile of Combantrin-1 (Mebendazole) based on documented acute clinical signs and potential severe systemic outcomes linked to high exposure.

Documented Overdose Manifestations

Acute overdosage commonly presents with transient gastrointestinal symptoms. These manifestations may include abdominal cramps, nausea, vomiting, and diarrhoea.

Severe Outcomes and Risk Factors

Severe systemic toxicities have been reported in the context of prolonged use or doses substantially higher than recommended. These toxicities affect multiple physiological systems and include hematologic findings such as agranulocytosis and neutropenia, as well as hepatic disturbances like hepatitis and reversible liver function disturbances. Glomerulonephritis and convulsions are also documented severe outcomes.

Specific population notes exist: convulsions have been reported in infants below the age of 1 year. Patients with impaired hepatic function may be at increased risk of higher systemic plasma levels following overexposure.

Regulator-Mandated Emergency Actions

Regulatory authorities mandate that individuals contact a poison control center or emergency room at once if overdosage is suspected. Immediate medical help is required for any suspected overdose event or the observation of severe signs.

Management for overdosage is primarily symptomatic and supportive, as no specific antidote is known. Procedural steps documented in official labeling include the potential administration of activated charcoal, and professional monitoring of blood counts and liver function may be required.

Therapeutic Uses of Combantrin-1

What Combantrin-1 Treats: Main Uses and Benefits

Combantrin-1 (Mebendazole) is an anthelmintic agent commonly used to address the symptomatic burden of intestinal parasitic infections. The medication is applied in clinical settings that involve parasitic conditions, relevant for easing conditions presenting with acute or episodic manifestations. It is primarily used to help eliminate the causative organisms, which include threadworm (pinworm), common roundworm, hookworm, and whipworm.

The primary purpose is relevant for easing symptoms that interfere with daily comfort, such as severe perianal itching and gastrointestinal discomfort. As part of managing the parasitic condition, the treatment contributes to improved comfort during periods of heightened symptoms and may assist with maintaining functional stability. It is commonly used to help with symptoms that interfere with daily functioning.

“The use is relevant when short-term symptomatic assistance is needed in contexts involving close-contact groups to support general well-being.”


Quick Fact: Relief for Disrupted Comfort The medication is relevant for easing symptoms that interfere with daily routine, such as sleeplessness caused by nocturnal itching, and generally plays a role in managing the potential for re-infestation within close-contact groups.


Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Combantrin-1?

The population eligibility for Combantrin-1 (Mebendazole) is strictly defined by regulatory labeling, outlining specific age restrictions, clinical conditions, and physiological states that determine appropriate use.

Populations for Whom Use is Contraindicated

Population Group Restriction Status
Children under 1 year of age Contraindicated
Hypersensitivity Contraindicated (known allergy to Mebendazole or its excipients)

Age-Related Eligibility Rules

Use is established for adults and children 2 years of age and older. Use in children aged 1 year to 2 years is restricted, permitted only if the potential benefit outweighs the potential risk. Furthermore, data are insufficient to determine the appropriate status for geriatric patients (aged 65 years and older).

Physiological and Conditional Restrictions

Physiological State Regulatory Status
Pregnancy Contraindicated / Not Recommended
Lactation Caution should be exercised (limited data)

Patients receiving prolonged or high-dose therapy may require periodic assessment of hepatic (liver) function, reflecting regulatory caution in this context.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the formally documented interaction patterns for Combantrin-1 (Mebendazole) based on authoritative government regulatory sources.

Mandatory Avoidance Combination

The regulatory profile mandates that co-administration of Mebendazole with Metronidazole must be avoided. This restriction is based on post-marketing reports that indicate a risk of severe adverse skin reactions, specifically Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), when these two medicines are used together.

Drug-Drug Pharmacokinetic Interactions

Co-administration with certain medicinal products can formally alter the plasma concentration and exposure of Mebendazole:

  • Increased Exposure: Co-use with Cimetidine may increase Mebendazole plasma levels. This effect is a documented pharmacokinetic interaction resulting from the inhibition of Mebendazole’s clearance.
  • Decreased Exposure: Co-administration with potent enzyme inducers, such as antiepileptic agents like Phenytoin, Carbamazepine, or Fosphenytoin, can significantly reduce Mebendazole serum concentrations. This interaction stems from the enhanced metabolism and clearance of Mebendazole.

Interactions with Food and Conditions

  • Food Interaction: Consumption of food, particularly a fatty meal, is officially documented to increase the systemic absorption of Mebendazole.
  • Population Note: Patients with pre-existing hepatic impairment (liver disease) may experience higher plasma levels of Mebendazole due to the compromised clearance of the medicine through the liver.

Mechanism of Action

The active moiety, pyrantel, selectively accumulates within the gastrointestinal tract lumen due to the poor aqueous solubility of its pamoate salt form, which minimizes systemic absorption. The drug functions as a depolarizing neuromuscular blocking agent in susceptible nematodes. Its primary biological targets are the nicotinic acetylcholine receptors (nAChRs) expressed on the somatic muscle cells of the helminth. Pyrantel acts as a selective agonist at these receptors, initiating their sustained activation. This continuous receptor engagement leads to a persistent influx of cations and subsequent, prolonged depolarization of the parasitic muscle cell membrane. The intracellular consequence of this continuous excitation is an uncontrollable, non-relaxing spastic muscle contraction. The downstream cascade culminates in paralysis of the entire organism. The system-level physiological consequence for the parasite is the loss of its ability to maintain attachment to the host's intestinal wall.

Dosage and Administration Information

How to use Combantrin-1 — Official Administration Guidelines

Administration of this medicine is based strictly on established clinical protocols.


Administration Scope

Feature Administration Guideline
Route of administration Oral administration.
Dosing schedule For Pinworm: A 100 mg single dose or a 500 mg single dose is specified. For Roundworm, Hookworm, or Whipworm: A 100 mg dose is taken twice daily for 3 consecutive days, or a 500 mg single dose is administered.
Timing in relation to meals May be taken without regard to food intake.
Preparation requirements The chewable tablet must be chewed completely before swallowing. The tablet may alternatively be swallowed whole or crushed and mixed with food. For patients unable to chew, the tablet can be placed in a spoon with approximately 2 to 3 mL of water to form a soft mass.
Age-group administration rules The same dosage schedule applies to adults and pediatric patients 2 years of age and older (for 100 mg products) or 1 year of age and older (for 500 mg products).
Missed-dose rules If a dose is missed during the 3-day regimen, the dose should be taken as soon as possible, and the regular schedule resumed.
Special procedural conditions No special procedures (such as fasting or purging) are required before, during, or after treatment.

Instruction Classifications (High-Level)

Classification Parameter
Administration method type Oral (Chewable Tablet)
Frequency pattern Single dose (short-term) or Twice Daily (short-term)
Clinical Basis Standard Pharmaceutical Guidelines
Use-context constraints Must be administered without special dietary or purging requirements.

Resulting Procedural Structure

Official step sequence:

  • Determine the official regimen based on the specific infection being addressed.
  • Chew the tablet completely, or crush and mix with food, or swallow the tablet whole.
  • Administer the dose orally without requiring a change in diet or fasting.
  • If a 3-day course is prescribed, take the morning and evening doses on time.
  • Administer a second course of treatment 3 weeks after the initial treatment only if the infection is not cured.

Connection to the overall use protocol: The official use protocol establishes a 1-day or 3-day short-term, non-fasting, oral administration pattern. This structure mandates specific preparation steps for the chewable tablet and clearly defines the permissible interval for a subsequent course, ensuring the drug is used according to standard administration guidelines.

Recent Clinical Evidence

Research evidence / Overview of studies for Combantrin-1

Evidence for Use in Pinworm (Threadworm) and Common Roundworm Infections

Research exploring the medication's use for pinworm (Enterobius vermicularis) has relied primarily on short-term randomized controlled trials (RCTs) and systematic reviews. The evidence base also includes analyses from regulatory summaries of use. These studies have generally included both children (aged two years and older) and adults. Researchers monitored outcomes related to the Cure Rate (CR), which measures the complete absence of parasitic eggs at follow-up, typically assessed using a perianal swab test. Studies reported measurements of egg clearance rates in the assessed populations. Findings described patterns of change in parasitic egg counts in individuals who were evaluated within the short follow-up windows.

For common roundworm (Ascaris lumbricoides), the evidence base includes numerous RCTs, systematic reviews, and large-scale outcomes reports from public health programs. Research examined outcomes related to the Egg Reduction Rate (ERR), which tracks the percentage change in the number of eggs per gram (EPG) of feces, and the Cure Rate (CR). Studies reported measurements for both ERR and CR across numerous public health studies, with findings indicating a measurable change in these metrics. Findings described measured changes related to the reduction of A. lumbricoides eggs in the digestive system over the short study period. However, evidence remains limited regarding the long-term changes in parasitic burden in areas where reinfection is a common pattern.


Research Structure for Hookworm and Whipworm Infections

This part will outline the specific study designs and endpoints used in trials examining hookworm and whipworm infections. It will focus on describing the evidence base and the metrics researchers used, such as the egg reduction rate (ERR) and cure rate (CR).

For whipworm (Trichuris trichiura) infection, studies explored outcomes related to both the Cure Rate (CR) and the Egg Reduction Rate (ERR) using standard parasitological assessments. Studies reported patterns related to ERR following evaluation. However, reported CRs were sometimes noted to be lower and more variable across different trials compared to those documented for roundworm infections. Research highlights a notable variability in reported parasite reduction measurements across studies and geographic regions, and evidence provides limited clarity on the factors that lead to lower reported CRs in certain settings.

Key Studies & References

  1. Cochrane Review: Benzimidazoles for treating soil-transmitted helminth infections
  2. Review on the efficacy and effectiveness of anthelmintic drugs against geohelminths (2022)

Frequently Asked Questions (FAQ)

Common questions about Combantrin-1 (FAQ)

Q: What is the active ingredient in Combantrin-1?

A: The active ingredient in Combantrin-1 is mebendazole. This compound is classified as an anthelmintic, a type of medication used to help manage parasitic worm infections.

Q: How does Combantrin-1 work?

A: Combantrin-1 (mebendazole) works by interfering with the worm's ability to absorb glucose (sugar), which is essential for its survival. This action, based on regulatory information, ultimately leads to the depletion of the worm's energy and its subsequent removal from the body.

Q: What should I do if I miss a dose of Combantrin-1?

A: Combantrin-1 is typically used as a single-dose treatment, according to the label instructions. If you have any concerns about administration or believe you may have missed part of the prescribed course, it is important to consult a healthcare professional for specific advice tailored to your situation. Do not attempt to take an extra dose without medical guidance.

Q: Can Combantrin-1 be used during pregnancy or while breastfeeding?

A: The use of mebendazole, the active ingredient in Combantrin-1, during pregnancy is often a subject for discussion with a healthcare provider. Current regulatory information suggests that the use of this medicine while pregnant or breastfeeding requires professional medical judgment to weigh the potential benefits against any potential risks. Always seek personalized advice from a doctor or pharmacist if you are pregnant, planning to become pregnant, or breastfeeding.

Q: What are some common side effects of Combantrin-1?

A: As with many medications, Combantrin-1 may be associated with side effects, although not everyone experiences them. Common side effects described in regulatory sources may include abdominal discomfort, diarrhea, or nausea. If you experience unexpected or severe reactions, you should promptly contact a healthcare professional.

How should Combantrin-1 be stored and disposed of?

Storage and Disposal Information

Combantrin-1 (Mebendazole) must be stored and disposed of according to official regulatory requirements to maintain stability and ensure safety.

Storage Conditions

Condition Regulatory Requirement
Temperature Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C (86 F).
Environment Keep the medicine in a cool, dry place. The product should not be stored in the bathroom or near high heat sources.
Safety The medicine must be kept strictly out of the sight and reach of children, often recommending a locked cupboard.

Disposal Instructions

Expired or unused product should be handled according to local requirements. The primary method for disposal is utilizing community drug take-back programs. If no take-back program is available, the medicine must be prepared for household trash by mixing it with an undesirable substance (such as used coffee grounds or kitty litter) and placing the mixture in a sealed container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Combantrin-1 found in:

A-Z Index: